Investigation of SARS-CoV-2 Seroprevalence and Factors Associated with Seropositivity in a Community Setting

ICR 202004-0920-015

OMB: 0920-1293

Federal Form Document

Forms and Documents
Document
Name
Status
Form
New
Form
New
Supplementary Document
2020-04-22
Supplementary Document
2020-04-22
Supplementary Document
2020-04-22
Supplementary Document
2020-04-22
Supplementary Document
2020-04-22
Supporting Statement B
2020-04-24
Supporting Statement A
2020-04-24
IC Document Collections
ICR Details
0920-1293 202004-0920-015
Historical Active
HHS/CDC 0920-20ND
Investigation of SARS-CoV-2 Seroprevalence and Factors Associated with Seropositivity in a Community Setting
New collection (Request for a new OMB Control Number)   No
Emergency 04/27/2020
Approved with change 04/27/2020
Retrieve Notice of Action (NOA) 04/27/2020
Approved consistent with CDC’s commitment to transparently report the impacts of test characteristics (including sensitivity and specificity) and sampling error on the precision of the results from each site
  Inventory as of this Action Requested Previously Approved
10/31/2020 6 Months From Approved
9,680 0 0
2,420 0 0
0 0 0

The goal of this information collection is to (1) determine the extent of infection in communities as determined by overall SARS-CoV-2 seroprevalence; and (2) determine factors associated with SARS-CoV-2 seropositivity among persons residing in areas with evidence of community transmission. The resulting data will be used to inform decisions about prevention and control strategies as well as community mitigation interventions.
An Emergency Request is being submitted for data that will be used immediately by CDC’s emergency COVID-19 response at the national level, and by state and local health departments, to understand the cumulative incidence in a given population within their jurisdiction. Additionally, antibody seropositivity data could supplement data on medically attended infection rates and contribute to describing the overall burden of COVID-19. Data collected during this investigation is essential to developing and assessing public health prevention measures by contributing to modeling estimates to inform decisions about prevention and control strategies as well as community mitigation interventions in the U.S. response to COVID-19; thus, improving the overall public health response.

US Code: 42 USC 241 Name of Law: Public Health Service Act
  
None

Not associated with rulemaking

No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 9,680 0 0 9,680 0 0
Annual Time Burden (Hours) 2,420 0 0 2,420 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
This is a New Emergency Request titled, “Investigation of SARS-CoV-2 Seroprevalence and Factors Associated with Seropositivity in a Community Setting”.

$901,168
Yes Part B of Supporting Statement
    Yes
    No
No
No
No
Uncollected
Odion Clunis 770 488-0045 lta2@cdc.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
04/27/2020


© 2024 OMB.report | Privacy Policy